Related Experiment Video

Updated: Nov 2, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.9K

CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer

Zhan Shi1, Ding Wu2, Hao Xu3

  • 1Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FEBS Open Bio
|June 11, 2021
PubMed

Insights

High mobility group AT-hook 2 (HMGA2) promotes chemoresistance in cervical cancer by interacting with casein kinase II A1 (CSNK2A1). Inhibiting CSNK2A1 may overcome cisplatin resistance, improving cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chemoresistance limits anti-cancer drug effectiveness, particularly in cervical cancer prevalent in developing nations.
  • High mobility group AT-hook 2 (HMGA2) is an oncogenic protein implicated in tumor development, but its role in cervical cancer chemoresistance is unknown.

Purpose of the Study:

  • To investigate the role of HMGA2 in cisplatin resistance in cervical cancer.
  • To explore the interaction between HMGA2 and casein kinase II A1 (CSNK2A1) in this context.

Main Methods:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify protein interactions.
  • Immunofluorescence to confirm co-localization of HMGA2 and CSNK2A1.
  • Immunoprecipitation assays to detect protein binding.
  • Treatment with CX-4945, a CSNK2A1 inhibitor.

Main Results:

  • HMGA2 is highly expressed in cervical cancer and inversely correlated with cisplatin-induced cell death.
  • HMGA2 interacts with and co-localizes with CSNK2A1 in the nucleus.
  • Cisplatin treatment enhances the interaction between CSNK2A1 and HMGA2, leading to HMGA2 phosphorylation.
  • CSNK2A1 inhibition by CX-4945 reduces HMGA2 phosphorylation and sensitizes cells to cisplatin.

Conclusions:

  • CSNK2A1-dependent phosphorylation of HMGA2 contributes to cisplatin resistance in cervical cancer.
  • HMGA2 phosphorylation presents a potential predictive biomarker and therapeutic target for enhancing chemotherapeutic efficacy.
Keywords:
CSNK2A1HMGA2cervical cancerchemoresistancecisplatin

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K